Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This has been a swing for me for awhile. We broke $2.52 today which was a key level. Next break is $2.79, and then $3.02 is the 50dma. Not a day trade for me here.
* * $FCSC Video Chart 05-25-18 * *
Link to Video - click here to watch the technical chart video
Thanks !! FCSC
A 5 for 1 RS went into effect this morning. So yesterday's close of .631 became $3.155. All shares were reduced to a 1/5 of what they were. Other than that, no new news to explain the spike to $5.17. The float is so low now, that any buying can cause it to rise real fast.
Hi what did I miss? Fcsc
Looks like you didn't need to worry short term either. I sold my last bunch at $5.10. Total profit was three grand. Very happy with that. GLTY $FCSC
Well I already own it. Looks like it will open down. $3.155 is the adjusted close, and the ask is $3.09 in pre-market right now.
Long term I am not worried because the science is good (IMO)
Short term .. whatever it opens at (say $3.27) it will drop asap !!
It might even go under a buck in a few days or weeks. Wait til then and then buy !!!!
Do not grab it up today !! Just my opinion. I hope I am wrong and that it does go up. Seen this drop to many time on reverse splits.
Do your own DD
Voted, approved, happening tomorrow, hence the BS pump news to print what they can before the meeting....should be able to grab more next week at a huge discount, 30% or more down if interested
Remember this - you were warned.
RS effective Tomorrow, massive failed scam.
RS vote was in a filing last month, so nothing new. Tomorrow morning is the annual meeting. It would authorize the board to do so, but the timing would be unknown.
I listened to the whole call and did not hear that:
http://ir.fibrocell.com/phoenix.zhtml?p=irol-eventDetails&c=253777&eventID=5271653
Was this something announced earlier, or on the website? I am going to take a look now. Thanks
Possible, not likely for an extended period without monumental news. Negligible shorts, RS imminent. Hope for bigger news than today or a pump of sorts. Otherwise, lower IMO. But, hope for something to help max the AS before RS, quite possible touches a $1. If not, should trade post RS as long as u don't hold through should be OK. Either way, worth watching, low float, moves quickly when someone is buying IMO.
Thank you for opportunity to load up b4 it’s $1
RS vote in 2 days puts a damper on things....should try to run it up before RS a bit though...
Oh I know it's good, but the stock had a bad reaction to whatever was said in the conf call. This was at $1.09 in pre, it's about to go back to .80 here.
Read the news, it's good...meeting the 23rd as well
Not sure what they are saying on the conf call, but it must be terrible.
C.C. @ 8:30 this morning > up 20% @ 1.00
Data looks better than ABEO data... Once we start phase 2 we should be trading between 2 to 3 dollars per share
Data looks great, here is the link to the presentation:
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzE2NTN8Q2hpbGRJRD02OTQ0NzE=
Fun right now
Apparently news is out
AH trading looking good
As do I. Suspect Monday will be fun.... lead drug data looked good last fall , will be presented tomorrow
These guys were mentioned in the Philly Business Journal not too long ago regarding the possibility of FDA priority review vouchers which could potentially be worth a lot of money if they got approval. Not sure how true.
But this could be a steal at these levels.
Who knows, but I like the risk/reward here.
A lot of 6 digit trades today- looks like we’re expecting a nice presentation tomorrow
Yes, but retreating now in pre. More buying opps may come our way at the open.
Yes Nice Move here. FCSC. Loading some yesterday morning.
Lets continue this run...tomorrow
Great close here. .96. Should see $1+ tomorrow. $FCSC
* * $FCSC Video Chart 05-17-18 * *
Link to Video - click here to watch the technical chart video
.9399 new HOD. Does this trade in AH? Could be wild this afternoon.
Word has FCSC lucrative partnership news coming.
New HOD .88! Dollar should be coming. $FCSC
Monday pps FCSC over 2pps.News on the way!Epic squeeze coming.
Gap to fill at a dollar. Obviously if results are good Monday, could see a mega move. This hit $4.64 about a year ago. $FCSC
FSCS Nice moves here. Any thoughts on where this might be heading? Data release on Monday?
thanks
Only 15 million shares outstanding. More then 50% held by institutions. Every time we see heavy volume the stock moves up. The product is a great one with little side effects. I also believe the product line may have an over the counter application.
IMHO
What makes you think it's that??
When this stock moves it’s gonna be a 10 timer. Can’t wait for the day
Proposal 2!
They caught me this time last year..... not again!!!!
FCSC Gonna EXPLODE so hard!!! So much coming down the pipe!!!Another beautiful sign is that Institutional BUYING has continued to increase rapidly! NO-BRAINER!!!!!
Consider yourself very BLESSED to be a shareholder at current valuations! .55-.60 HOLD TIGHT!!! Earnings release on Monday as well as MAJOR update announcements!!! MBD
Next week MAJOR breakout NORTHWARDS!!! BLOCKBUSTER earnings release coming imo! Potential announcement of a buyout or merger POSSIBLY as well!!! MBD
Followers
|
105
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
7054
|
Created
|
01/09/08
|
Type
|
Free
|
Moderators |
Fibrocell Science, Inc. is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications.
Welcome to the new Fibrocell Science, Inc. and our new web site. I am pleased to have this opportunity to share my enthusiasm with you as Fibrocell’s Chairman of the Board of Directors.
We have been extremely busy charting the course for Fibrocell as a biotechnology company focused on the power of regenerative fibroblast cells for aesthetic, medical and scientific applications.
We have a challenging and exciting path before us as we continue to prepare for the U.S. Food & Drug Administration response to the biologics license application (BLA) we submitted in March 2009 for the use of Laviv™ (azficel-T)*, Fibrocell Science’s lead therapy, for the treatment of moderate to severe nasolabial fold wrinkles. The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee, which reviewed our therapy on October 9, 2009, voted 11 yes to 3 no that the data presented demonstrated efficacy, and 6 yes to 8 no that the data demonstrated safety, both for the proposed indication.
We are pleased to begin operations under Fibrocell Science, Inc., having reorganized the former Isolagen, Inc. and significantly reduced the company’s debt from US $81M to US $6M. We now look forward to an ambitious evaluation of our clinical priorities to maximize the potential use of our therapy in additional indications such as full-face rejuvenation, acne scars, burn scars and dental applications.
We have considerable work before us at Fibrocell Science, and we welcome the challenge. I join Fibrocell with extensive commercial experience from GlaxoSmithKline, where I most recently served as senior vice president, Pharmaceuticals and Vaccines. I am proud to have a strong management team helping guide this new company, including Declan Daly, former Isolagen chief executive officer, who was instrumental in our reorganization and remains committed to the company’s success.
Thank you for your interest in the new Fibrocell Science, Inc.
Sincerely,
David Pernock
Chairman
Fibrocell Science, Inc.
Fibrocell Therapy is an investigational autologous cell therapy. In the Fibrocell Science patented process, a patient’s own natural fibroblasts are extracted, multiplied and re-injected as personalized therapy. Fibroblasts are cells that contribute to the formation of connective tissue fibers. These matrix fibers are critical to the strength and elasticity of the skin.
Broadly, the regenerative effects of fibroblasts include:
- The ability to synthesize the extracellular matrix components and, thus, to improve skin texture,
- The secretion of matrix fibers, including collagen, and
- Playing a critical role in wound healing and tissue repair.
The Company prepares the Fibrocell Therapy through a streamlined process that begins with removing a small sample of cells from behind a patient’s ear and sending that sample to the Fibrocell cGMP facility. The process expands fibroblasts into tens of millions of new cells, which are then formulated into an autologous cellular therapy. Cells are frozen and used for multiple treatment sessions. The therapy is reintroduced into the patient’s skin by injection, which we believe results in an increase in the local fibroblast population, collagen formation and assists the body’s own regenerative healing process. In controlled clinical studies, a significant improvement in the appearance of nasolabial fold wrinkles was observed after injecting Fibrocell Therapy.
Regenerative fibroblast cells may have potential in use for broad aesthetic, medical and scientific applications. The Fibrocell Therapy for aesthetics, azficel-T, proposed brand name Laviv™, is currently under review by the FDA for the treatment of moderate to severe nasolabial fold wrinkles. Fibrocell Science, Inc. is planning to continue studies for additional aesthetic and therapeutic indications for azficel-T.
The company manufactures its cell therapy at a cGMP manufacturing facility in Pennsylvania.
Fibroblasts are cells that contribute to the formation of connective tissue fibers. Fibrocell's future scientific focus will be on regenerative medicine that leverages the direct and indirect therapeutic benefit of fibroblasts.
Fibrocell has submitted a biologics license application to the U.S. Food & Drug Administration (FDA) based on its Phase III clinical trials evaluating the efficacy and safety of its azficel-T in treating moderate to severe nasolabial fold wrinkles in patients older than 18 year of age.
In addition to wrinkle correction, Fibrocell has obtained statistically significant results in a Phase II/III acne scar clinical trial and a Phase II open label full face rejuvenation study. Fibrocell also has results in early burn scars and periodontal disease studies.
Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence.
Fibrocell Therapy is an investigational autologous cell therapy. In the Fibrocell Science patented process, a patient's own natural fibroblasts are extracted, multiplied and re-injected as personalized therapy to regenerate skin. Fibroblasts are cells that contribute to the formation of connective tissue fibers. The Fibrocell Therapy for aesthetics, azficel-T, proposed brand name Laviv™ is currently under review by the FDA for the treatment of moderate to severe nasolabial fold wrinkles.
Fibrocell Science, Inc. is planning to continue studies for additional aesthetic and therapeutic indications for its Fibrocell Therapy, which is manufactured at a cGMP cell therapy manufacturing facility at its headquarters in Pennsylvania.
OCTOBER 09, 2009
Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
OCTOBER 06, 2009
Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |